To move Epitalon from experimental to evidence-based, several developments are essential: Randomized, double-blind, placebo-controlled clinical trials, ideally targeting specific endpoints (sleep, immune aging, telomere attrition) Toxicology and long-term safety studies, including exploration of stereoisomer effects and off-target consequences Validated delivery systems (e.g., dendrimer-conjugates, transdermal patches) that make real-world use feasible Pharmacodynamic biomarkers, to identify responders and track efficacy objectively over time Epitalon is not snake oil, but its also not a magic bullet
10.1016/j.jdiacomp.2018.01.015 9 BeatonM
doi: 10.1038/d41586-021-03614-z 32 CampoloJ.BernardiS.CozziL.RocchiccioliS.DellanoceC.CecchettiniA.et al
doi: 10.3389/fcell.2024.1435125 Received 19 May 2024 Accepted 27 June 2024 Published 11 July 2024 Volume 12 - 2024 Edited by Takehito Ouchi, Tokyo Dental College, Japan Reviewed by Kui Xu, Anhui University of Chinese Medicine, China Xiaolei Li, University of Pennsylvania, United States Updates Copyright 2024 Zheng, Liu, Sun and Meng
Atm inhibition decreases lens opacity in a rat model of galactose-induced cataract
doi:10.1038/s41467-020-17813-1